among these patients and MM remains incurable; thus, new therapeutic approaches are needed. 1 Carfilzomib, an epoxyketone proteasome inhibitor, binds selectively and irreversibly to the constitutive proteasome and immunoproteasome. A recent phase 3 (ASPIRE) study evaluated the combination of carfilzomib, lenalidomide and dexamethasone (CLd) and showed that this combination resulted in a 31% decrease in the risk of disease progression or death compared with lenalidomide and dexamethasone, and an increase of 8.7 months in the median progression-free survival (PFS) of patients with relapsed MM. 3 In a phase 3, head-to-head comparison study with bortezomib (ENDEA-VOR), which included patients from Europe, North America, South
America and the Asia-Pacific region, carfilzomib and dexamethasone (Cd) provided a significant and clinically meaningful reduction in the risk of death compared with bortezomib and dexamethasone. 4 Both the CLd and Cd twice-weekly regimens have been approved in the USA, Europe and Japan based on the results of these phase 3 studies. Furthermore, studies with carfilzomib monotherapy, 5 Cd 6 and CLd 7 have been conducted in Japan.
Although the efficacy of twice-weekly carfilzomib, as monotherapy and in combination with other drugs (Ld and dexamethasone), has been demonstrated, the twice-weekly dosing schedule results in some inconveniences for patients. Therefore, a more convenient dosing schedule can improve treatment compliance, and weekly treatment alternatives are highly sought after.
Recently, a phase 1/2 study (CHAMPION-1) in the USA evaluated weekly Cd in relapsed or refractory MM (RRMM) patients. 8 In that study, the overall response rate (ORR) at 70 mg/m 2 was 77%, and the median PFS was 12.6 months, indicating that further assessment of the weekly dosing was warranted. The objectives of this study were to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of weekly Cd in Japanese patients with RRMM.
| MATERIALS AND METHODS

| Study design and ethical considerations
This was an open-label, multicenter, phase 1 study conducted in 4 centers in Japan. The study started in December 2012 and is currently ongoing. For the weekly Cd cohort, the first patient was 
| Participants
The inclusion criteria were as follows: age ≥20 years; Eastern Coop- 
| Treatment
Carfilzomib was administered by 30-minute intravenous infusion on 
| Study outcomes and assessments
In this study, the primary objectives were to evaluate the tolerability 
| Statistical analysis
The planned sample size was 6 patients. For this cohort, the sample size was selected considering the number of patients required to successfully evaluate tolerability and PK.
Study populations for the analysis were defined as follows: The safety set (SAF) comprised the patients who received at least 1 dose of the study drug. The full analysis set comprised the patients in the SAF who were GCP compliant, met the main inclusion criteria, and in whom efficacy could be analyzed at least once post-dose. The population for the PK analysis comprised the patients who received at least 1 dose of the drug, were GCP compliant, and had a plasma concentration measurement result. PK parameters were calculated using Phoenix WinNonlin version 6.2.1 (Certara L.P., Princeton, NJ, USA 3 | RESULTS
| Patients and treatment
A total of 6 patients with RRMM were enrolled between March 2015 and June 2015. All 6 patients were evaluable for safety and efficacy analyses. Baseline demographic and clinical characteristics of patients are presented in Table 1 . Four out of 6 patients (4/6, 66.7%) were male, and the median age was 68.0 (range, 63-80) years. The median number of previous regimens was 4.5 (range, 4-8). All patients had previous therapies with bortezomib and immunomodulatory drugs, including lenalidomide and/or thalidomide.
One out of 5 evaluable patients had t(4;14) and was categorized as having high-risk cytogenetics.
Patient exposure to the study drug is summarized in Table 2 .
The median number of cycles was 15 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 
| Tolerability/safety
One out of 6 patients experienced a DLT, and the tolerability of the weekly Cd regimen with 20/70 mg/m 2 was confirmed. The DLT was grade 3 thrombotic microangiopathy, which occurred on Day 11 of Cycle 1 and was considered a serious event. All 6 patients (100%) experienced at least 1 grade ≥3 AE. Five out of 6 patients (83.3%) experienced serious AE, which were also considered serious adverse drug reactions (ADR). All AE of any grade with incidence ≥20% and grade ≥3 AE are shown in Table 3 .
The most common AE (occurring in more than 3 patients) 
| Efficacy
All 6 patients were evaluable for response. The ORR and CBR are presented in 
| PK
The PK parameters of carfilzomib are shown in Table 6 . , with a T 1/2 of 0.900 ± 0.0740 hours (Figure 3) . The C max of carfilzomib after administration of 70 mg/m 2 was 2500 ± 777 ng/mL, and AUC last was 1250 ± 285 ng*h/mL. The C max and AUC last increased in a dose-dependent manner.
| Pharmacodynamics
The proteasome activities in whole blood and peripheral blood mononuclear cells are shown in Figure 4A ,B. The proteasome activity was inhibited 1 hour after administration on Days 1 and 8 of Cycle 1 and on Day 1 of Cycle 2 with ≥90% inhibition.
| DISCUSSION
This was the first study in which a weekly Cd regimen with carfilzomib at a dose of 20/70 mg/m 2 was administrated to Japanese RRMM patients. The weekly Cd regimen was generally well-tolerated and showed an improved efficacy in heavily pretreated Japanese RRMM patients.
The US phase 1/2 study (CHAMPION-1) was the first study to evaluate weekly dosing of Cd. 8 In the CHAMPION-1 study, the maximum tolerated dose of weekly Cd was determined to be 20/70 mg/ m 2 , and this dose was shown to be effective with an ORR of 77%. When comparing the present efficacy findings with those of CHAM-PION-1, the ORR results were similar in both studies at 83.3% and 77%, respectively. Regarding the safety profile, the incidences of pyrexia, pneumonia, weight increase, upper respiratory tract infection and hypophosphatemia were higher in the present study. This difference may be influenced by the number of patients in both studies and the status of previous therapies.
Although cross-trial comparisons are difficult, when we compare the findings of the present study with those of previous Japanese studies, the ORR of 83.3% with Cd in the present study was similar to that in a previous study by Suzuki et al 7 (88.5%) in which carfilzomib was administered at a dose of 20/27 mg/m 2 in combination with lenalidomide and dexamethasone. In contrast, the ORR was comparable to the data reported in previous studies of twice weekly carfilzomib monotherapy at a dose of 20/27 mg/m 2 (22.5%) 5 and 20/ 45 or 20/56 mg/m 2 (57.1%). 6 The present efficacy findings indicate Bortezomib is the first proteasome inhibitor to be tested and is widely used in clinical practice, and ixazomib is a novel oral proteasome inhibitor. The efficacy of carfilzomib was shown in the present study, which was conducted in a population that included patients resistant to bortezomib. In addition, the superiority of carfilzomib over bortezomib in terms of PFS was previously demonstrated in a head-to-head comparison in ENDEAVOR, in which OS was also confirmed to be superior based on follow-up data. 4 In a study of ixazomib, PFS was reported to be 20.6 months in patients who received ixazomib with lenalidomide and dexamethasone. 11 In the ASPIRE study, PFS was reported to be 26.3 months in patients who received CLd. 3 These data suggest that the efficacy of carfilzomib is comparable to that of ixazomib. As ixazomib is an oral agent, it may be considered more convenient than drugs that require intravenous infusion. However, the weekly Cd regimen used in the present study is more convenient than twice-weekly regimens and may improve carfilzomib compliance in this respect.
New and clinically significant safety findings were raised in the present study as 2 patients experienced microangiopathy-related events (thrombotic microangiopathy and thrombotic The PK parameters of carfilzomib, C max and AUC last increased in a dose-dependent manner. These findings are consistent with those of 3 previous studies assessing PK parameters of carfilzomib at different doses in Japanese subjects. [5] [6] [7] Furthermore, the pharmacodynamics analysis revealed that proteasome activities were well inhibited (≥90%) by the carfilzomib administration, which is also consistent with previous Japanese studies. 5, 6 This study had several limitations: notably, the small sample size, the lack of a comparator and the fact that it enrolled only Japanese patients.
In conclusion, the weekly Cd regimen at a dose of 20/70 mg/m 2 was well-tolerated among Japanese patients with RRMM. However, careful attention needs to be paid to the occurrence of serious AE, such as infectious events and thrombotic microangiopathy. Further studies should be conducted to confirm the efficacy of high-dose weekly carfilzomib in combination with dexamethasone and to determine the incidence of AE related to this regimen. Although this was a phase 1 study with a small number of patients, we believe that our results could be the basis for the further development of carfilzomib treatment in view of the safety profile, including microangiopathyrelated events, and efficacy.
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